Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00639171|
Recruitment Status : Completed
First Posted : March 20, 2008
Last Update Posted : October 11, 2017
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||13 participants|
|Official Title:||Clinical Implementation and Evaluation of MR Spectroscopy for Breast Cancer Detection|
|Study Start Date :||November 2005|
|Primary Completion Date :||August 2015|
|Study Completion Date :||August 2015|
Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00639171
|United States, New York|
|SUNY Upstate Medical University|
|Syracuse, New York, United States, 13210|
|Principal Investigator:||Andrzej Krol, PhD||State University of New York - Upstate Medical University|